Roche Holding AG | Cash Flow

Fiscal year is January-December. All values CHF Millions.
2013
2014
2015
2016
2017
Net Income before Extraordinaries
11,373
9,535
9,056
9,733
8,825
Depreciation, Depletion & Amortization
2,381
2,623
3,640
3,941
3,887
Other Funds
1,301
1,582
716
899
244
Funds from Operations
14,733
15,247
14,743
15,199
16,979
Changes in Working Capital
209
258
431
1,023
427
Net Operating Cash Flow
14,524
14,989
14,312
14,176
17,406
Capital Expenditures
2,854
3,334
4,110
5,145
4,213
Sale of Fixed Assets & Businesses
67
64
91
151
116
Purchase/Sale of Investments
1,644
539
1,922
649
2,169
Net Investing Cash Flow
1,353
12,039
4,266
4,537
6,484
Cash Dividends Paid - Total
6,238
6,617
6,807
6,909
7,019
Issuance/Reduction of Debt, Net
5,831
5,211
2,056
1,414
3,209
Net Financing Cash Flow
13,370
2,988
9,579
9,222
10,472
Net Change in Cash
530
258
11
432
556
Free Cash Flow
12,073
12,023
10,844
10,032
13,897
Deferred Taxes & Investment Tax Credit
-
974
1,070
302
1,423
Net Assets from Acquisitions
233
9,633
2,142
74
280
Other Sources
23
325
-
-
62
Exchange Rate Effect
331
220
478
15
106
Other Uses
-
-
27
118
-

About Roche Holding

View Profile
Address
Grenzacherstrasse 124
Basel Basel-Stadt (Basle Town) 4070
Switzerland
Employees -
Website http://www.roche.com
Updated 09/14/2018
Roche Holding AG operates as a research healthcare company. It operates through the following segments: Diagnostics and Pharmaceuticals. The Pharmaceutical segment refers to development of medicines in the field of oncology, immunology, ophthalmology, infectious diseases and neuroscience.